COVID-19 Vaccination Status and Hesitancy among Breast Cancer Patients after Two Years of Pandemic: A Cross-Sectional Survey

Weijing Liu,†‡, Yunhao Wu,†‡, Ruoning Yang, Ruixian Chen, Ya Huang, Xin Zhao, Min Xie, Qintong Li, Qiang Wang and Jie Chen

1 Department of Breast Center, West China Hospital, Sichuan University, Chengdu 610041, China
2 Mental Health Centre, West China Hospital, Sichuan University, Chengdu 610041, China
3 Departments of Obstetrics & Gynecology and Pediatrics, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Sichuan University, Chengdu 610041, China
* Correspondence: chenjiedoctor@wchscu.cn
† These authors contributed equally to this work.
‡ Current Address: No. 37, Guoxue Alley, Chengdu 610041, China.

Simple Summary: The coronavirus disease 2019 (COVID-19) vaccine has played an important role in preventing infection and adverse outcomes in immunocompromised cancer patients, especially in breast cancer, one of the common tumor types. However, there are limited reports of vaccination in breast cancer patients and these are limited by the timeliness of research investigations. This is a cross-sectional study of 1132 Chinese breast cancer patients aged 18 years and older, each of whom completed an online self-reported questionnaire. This study was conducted to describe the vaccination status, adverse effects and vaccine hesitancy towards future vaccinations or boosters among Chinese breast cancer patients after two years of the pandemic, to provide new perspectives for health promotion.

Abstract: Background: Patients with cancer show greater susceptibility and vulnerability to severe acute respiratory syndrome coronavirus 2 infection. However, data on the vaccination status among patients with breast cancer and any structured analysis of the factors influencing patients’ decisions regarding vaccines are lacking. Methods: This cross-sectional study on patients with breast cancer in China was conducted from 1 June 2022, to 17 June 2022. Every participant completed an online questionnaire about their vaccination status and any adverse reactions, and a scale based on the Health Belief Model (HBM) to assess the vaccination status of respondents and their willingness to receive following doses or boosters. Results: Among the 1132 participants, 55.2% had received a COVID-19 vaccine. The incidence of adverse events per dose was around 40%. Vaccine hesitancy of 61.9% was observed among patients who had not fully received three doses of vaccine or boosters. The only variable found to be associated with vaccine hesitancy was time since diagnosis \( p < 0.05 \). In the HBM scale, vaccine hesitancy was closely related to a low level of perceived susceptibility, a low level of perceived benefit, a high level of perceived barriers and a low level of agreement with doctors’ advice. Conclusions: For patients with breast cancer, perceived susceptibility, benefits and barriers should be prioritized, and the advice from authoritative doctors is a vital cue to action.

Keywords: COVID-19; booster vaccination; adverse event; breast cancer; vaccine hesitancy

1. Introduction

With the global epidemic of coronavirus disease 2019 (COVID-19) continuing for more than 2 years, patients with cancer show increased susceptibility and vulnerability due...
to their immunocompromised condition and have a high risk of developing COVID-19 related complications [1–4]. High mortality has been recorded among patients with solid or hematological malignancies infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [5,6]. As one of the largest cancer populations, patients with breast cancer account for a high percentage of SARS-CoV-2 infections [7,8] and thus require attention and medical support during the COVID-19 pandemic.

Patients with cancer should be considered a high-risk group for priority COVID-19 vaccination [9]. Despite the considerable uncertainty in vaccine efficacy, immune responses and adverse events, the UK Coronavirus Cancer Evaluation Project and other studies have supported the recommendation that a third dose or booster should be prioritized in patients with cancer because vaccine effectiveness declines faster in these groups than in the general population [10,11].

Vaccination rates among cancer patients remain low [6,12], which is indicative of hesitation regarding the vaccine [13,14]. Vaccine hesitancy refers to the delay in acceptance or refusal of safe vaccines despite the availability of vaccination services, and this phenomenon poses a major threat to global health [15]. Studies on vaccination status and attitudes toward COVID-19 vaccines among the cancer population in various countries have reported the incidences of vaccine hesitancy to be around 18–74% [16–20]. As the COVID-19 pandemic continues to ravage communities worldwide, the threat of vaccine hesitancy has become evident and urgent.

Current studies on the vaccination willingness of patients with breast cancer provide limited data on patient vaccination rates and self-reported adverse events. Any structured analysis of the reasons influencing patients’ decision regarding vaccines is also lacking. Thus, we conducted a cross-sectional survey of patients with breast cancer to investigate the current vaccination status and reported adverse events among the vaccinated population. Considering that the vaccination recommendation for COVID-19 worldwide is full vaccination with a booster dose, we designed a Health Belief Model (HBM)-based scale to analyze the cognitive and behavioral patterns in response to future vaccinations among individuals who have not received full vaccination or boosters. The HBM is a common tool to predict intention and behavior for influenza vaccination [21–23] and contains different dimensions, such as perceived susceptibility, perceived severity, perceived benefits, perceived barriers and cues to action. Vaccine hesitation has been associated with HBM dimensions [24,25].

With this study, we hope to provide evidence-based data to address the concerns of patients with breast cancer and to improve the coverage of the COVID-19 vaccination.

2. Methods
2.1. Study Design and Participants

This internet-based, cross-sectional study was conducted among patients with breast cancer in West China Hospital. The questionnaire was administered to individuals and collected via an online platform from 1 June 2022, to 17 June 2022. The study purpose was explained to these individuals and informed consent was obtained before the survey. The inclusion criteria for patients were as follows: (1) >18 years old, (2) diagnosed with breast cancer via a pathology test and (3) agreed to participate. This study was approved by the Clinical Test and Biomedical Ethics Committee of West China Hospital, Sichuan University (approval number: 2022649).

2.2. Survey and Data Collection

The questionnaire was designed by a panel of psychologists and clinicians and consisted of three parts: (1) demographics and clinical history, (2) vaccination status and adverse event and (3) vaccine hesitancy and HBM scale. The HBM scale was adopted from a similar work on vaccine acceptance and was proven to be effective and feasible [26]. Patients who had not been vaccinated yet or who had received one or two doses were instructed to answer relevant questions on their willingness to receive a future COVID-19
dose/booster in the scale, followed by a 5-point Likert HBM scale (1-strongly disagree, 5-strongly agree).

**Demographics and clinical history**: Sociodemographic information included age, marital status, education, number of family members, annual income (USD) and medical costs. Clinical history included time since diagnosis (year), comorbidity, number of comorbidities, treatment type and number of treatments.

**Vaccination status and adverse event**: Data on vaccination status, doses, types, time (before or after diagnosis) and adverse events for each dose were collected through several questions. Patients who received at least one dose of vaccine were asked to report any immediate (<48 h) and late (>48 h) adverse events.

**Vaccine hesitancy and HBM scale**: Patients who had not received the third dose/booster were asked about their willingness to receive future vaccination (Table S1). Cronbach’s alpha was calculated for the questions of each construct of the HBM to determine the internal consistency and reliability of our questionnaire. The HBM scale consisted of 18 items of 5 dimensions: perceived susceptibility (1–3 items; Cronbach’s alpha, 0.735), perceived severity (4–7 items; Cronbach’s alpha, 0.818), perceived benefits (8–10 items; Cronbach’s alpha, 0.856), perceived barriers (11–15 items; Cronbach’s alpha, 0.874) and cues to action (16–18 items; Cronbach’s alpha, 0.782). In general, a Cronbach’s alpha of more than 0.7 indicates the internal consistency of the item groups. A Kaiser–Meyer–Olkin test (0.757) and Bartlett’s test of sphericity \( p < 0.001 \) confirmed the adequacy of the sample for exploratory factor analysis.

2.3. Statistical Analysis

Data analysis was performed using IBM SPSS statistics software (IBM Corp. Hq Chicago, IL, USA. Version 24.0) and Tableau (Tableau Software, Seattle, WA, USA. Version 2021.1). Depending on the type of the variable, a chi-square test, Fisher’s exact test or Student’s \( t \)-test was used to compare the distribution of baseline characteristics among all patients. The dependent variable “Are you willing to get the future vaccination?” had two possible values: 0 = (“willing to be vaccinated”); 1 = (“hesitate/refuse to be vaccinated”). The scores for the HBM scale in each item were transformed to binary variables for logistic regression: 1 = (“strongly agree/agree”); 0 = (“neutral/disagree/strongly disagree”). Forward univariate and multivariate analyses based on Pearson’s chi-square tests were performed to determine the association between sociodemographic and clinical variables and reported adverse events/vaccine acceptance, and the values were presented as odds ratios (OR) with a 95% confidence interval (95% CI). All statistical tests were 2-tailed and \( p \) values < 0.05 were considered to be statistically significant.

3. Results

3.1. Sociodemographic and Clinical Characteristics of Participants

A total of 1170 questionnaires were collected, of which 38 duplicated questionnaires were excluded. Finally, 1132 patients were included in this study. Among all the patients, 625 (55.2%) received at least one dose of the COVID-19 vaccine and 507 (44.8%) had not been vaccinated. Among the vaccinated patients, 3.36% (21/625) received only one dose, 51.36% (321/625) received two doses and 45.28% (283/625) completed the third dose. A total of 453 patients reported their vaccine types, among which 436 (96.2%) received inactivated vaccines (including Beijing Institute of Biological Products Co., Ltd. Beijing, China, Wuhan Institute of Biological Products Co., Wuhan, China and Sinovac Life Sciences Co., Ltd. Beijing, China), 4 (0.9%) received adenovirus vaccines (CanSino Biologics Inc. Tianjin, China) and 13 (2.9%) received recombinant vaccines (Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. Hefei, China). Relevant information regarding all reported vaccines is listed in Table S2.

The patients were divided into vaccinated and nonvaccinated groups according to their vaccination status (Table 1). The age of all patients ranged 25–84 years with a median age of 49.2 years. No significant difference in age composition was observed between the
vaccinated and nonvaccinated groups \((p = 0.183)\), and 74.4% of all patients were between 40 and 59 years of age. The majority of patients who participated in the questionnaire (71.8%) were diagnosed <3 years ago, and nearly half of the vaccinated patients had been diagnosed within 1 year (56.0%). Among all the participants, 91.1% were married; 70.3% had high-school education or above; 87.1% had families with three or more members; 68.1% had an annual income of less than 15,000 USD; and 88.5% had medical insurance. These factors showed no statistically significant differences between the two groups.

**Table 1.** Baseline characteristics of patients.

| Variables                        | Vaccinated \(n = 625\) (%) | Non-Vaccinated \(n = 507\) (%) | Total \(n = 1132\) (%) | \(p\)-Value |
|----------------------------------|-----------------------------|-------------------------------|------------------------|-------------|
| **Age, year**                    |                             |                               |                        | 0.183       |
| <40                              | 105 (16.8)                  | 67 (13.2)                     | 172 (15.2)             |             |
| 40–59                            | 460 (73.6)                  | 382 (75.3)                    | 842 (74.4)             |             |
| ≥60                              | 60 (9.6)                    | 58 (11.4)                     | 118 (10.4)             |             |
| **Time since diagnosis, year**   |                             |                               |                        | <0.001      |
| <1                               | 350 (56.0)                  | 30 (5.9)                      | 380 (33.6)             |             |
| 1–3                              | 84 (13.4)                   | 348 (68.6)                    | 432 (38.2)             |             |
| 4–5                              | 82 (13.1)                   | 80 (15.8)                     | 162 (14.3)             |             |
| >5                               | 109 (17.4)                  | 49 (9.7)                      | 158 (14.0)             |             |
| **Marital status**               |                             |                               |                        | 0.335       |
| Married                          | 576 (92.2)                  | 455 (89.7)                    | 1031 (91.1)            |             |
| Unmarried                        | 16 (2.6)                    | 15 (3.0)                      | 31 (2.7)               |             |
| Others                           | 33 (5.3)                    | 37 (7.3)                      | 70 (6.2)               |             |
| **Education**                    |                             |                               |                        | 0.594       |
| Middle school and below          | 197 (31.5)                  | 139 (27.4)                    | 336 (29.7)             |             |
| High school                      | 101 (16.2)                  | 89 (17.6)                     | 190 (16.8)             |             |
| Technical secondary school       | 45 (7.2)                    | 44 (8.7)                      | 89 (7.9)               |             |
| College                          | 148 (23.7)                  | 123 (24.3)                    | 271 (23.9)             |             |
| Bachelor and above               | 134 (21.4)                  | 112 (22.1)                    | 246 (21.7)             |             |
| **Members in family**            |                             |                               |                        | 0.068       |
| 1–2                              | 74 (11.8)                   | 72 (14.2)                     | 146 (12.9)             |             |
| 3                                | 259 (41.4)                  | 230 (45.4)                    | 489 (43.2)             |             |
| 4                                | 149 (23.8)                  | 90 (17.8)                     | 239 (21.1)             |             |
| ≥5                               | 143 (22.9)                  | 115 (22.7)                    | 258 (22.8)             |             |
| **Annual income, USD**           |                             |                               |                        | 0.382       |
| <3000                            | 149 (23.8)                  | 121 (23.8)                    | 270 (23.9)             |             |
| 3000–15,000                      | 278 (44.5)                  | 223 (44.0)                    | 501 (44.3)             |             |
| 15,000–30,000                    | 125 (20.0)                  | 117 (23.1)                    | 242 (21.4)             |             |
| >30,000                          | 73 (11.7)                   | 46 (9.1)                      | 119 (10.5)             |             |
| **Medical cost**                 |                             |                               |                        | 0.106       |
| Self-paid                        | 47 (7.5)                    | 23 (4.5)                      | 70 (6.2)               |             |
| Insurance                        | 547 (87.5)                  | 455 (89.7)                    | 1002 (88.5)            |             |
| Others                           | 31 (5.0)                    | 29 (5.7)                      | 60 (5.3)               |             |
| **(Comorbidity)**                |                             |                               |                        |             |
| Hypertension                     | 58 (9.3)                    | 58 (11.4)                     | 116 (10.2)             | 0.233       |
| Dyslipidemia                     | 65 (10.4)                   | 64 (12.6)                     | 129 (11.4)             | 0.242       |
| Diabetes/Abnormal blood sugar    | 37 (5.9)                    | 41 (8.1)                      | 78 (6.9)               | 0.152       |
| Chronic lung disease             | 19 (3.0)                    | 32 (6.3)                      | 51 (4.5)               | 0.008       |
| Liver disease                    | 21 (3.4)                    | 26 (5.1)                      | 47 (4.2)               | 0.138       |
| Heart disease                    | 11 (1.8)                    | 12 (2.4)                      | 23 (2.0)               | 0.472       |
| Gastrointestinal disease         | 30 (4.8)                    | 41 (8.1)                      | 71 (6.3)               | 0.023       |
| Kidney disease                   | 13 (2.1)                    | 15 (3.0)                      | 28 (2.5)               | 0.344       |
| Neuropsychiatric disease         | 15 (2.4)                    | 18 (3.6)                      | 33 (2.9)               | 0.253       |
| Rheumatic disease and asthma     | 34 (5.4)                    | 42 (8.3)                      | 76 (6.7)               | 0.057       |
| **Number of comorbidities**      |                             |                               |                        | <0.001      |
| 0                                | 389 (62.2)                  | 252 (49.7)                    | 641 (56.6)             |             |
| 1                                | 173 (27.7)                  | 173 (34.1)                    | 346 (30.6)             |             |
| ≥2                               | 63 (10.1)                   | 82 (16.2)                     | 145 (12.8)             |             |
Table 1. Cont.

| Variables          | Vaccinated n = 625 (%) | Non-Vaccinated n = 507 (%) | Total n = 1132 (%) | p-Value |
|--------------------|------------------------|-----------------------------|--------------------|---------|
| (Treatment)        |                        |                             |                    |         |
| Surgery            | 339 (45.8)             | 214 (57.8)                  | 553 (51.1)         | <0.001  |
| Endocrine therapy  | 287 (45.9)             | 347 (68.4)                  | 634 (56.0)         | <0.001  |
| Chemotherapy       | 314 (50.2)             | 119 (23.5)                  | 433 (38.3)         | <0.001  |
| Radiotherapy       | 95 (15.2)              | 82 (16.2)                   | 177 (15.6)         | 0.654   |
| Targeted therapy   | 110 (17.6)             | 92 (18.1)                   | 202 (17.8)         | 0.811   |
| Others             | 22 (3.5)               | 36 (7.1)                    | 58 (5.1)           | 0.007   |
| Number of treatments |                      |                             |                    | 0.003   |
| 0                  | 58 (9.3)               | 51 (10.1)                   | 109 (9.6)          |         |
| 1                  | 234 (37.4)             | 237 (46.7)                  | 471 (41.6)         |         |
| ≥2                 | 333 (53.3)             | 219 (43.2)                  | 552 (48.8)         |         |

Data on comorbidities and treatment modalities were also recorded. Nearly half of all the patients had at least one comorbidity. The vaccinated patients seemed to have fewer comorbidities than the nonvaccinated patients (62.2% vs. 49.7%, p < 0.001). Among the patients with comorbidities, hyperlipidemia (11.4%) and hypertension (10.2%) were the most common diseases, followed by diabetes/dysglycemia (6.9%), rheumatism and asthma (6.7%) and gastrointestinal disorders (6.3%). Patients who had been receiving at least two treatment modalities accounted for 48.8%. Endocrine therapy (56.0%) and surgery (51.1%) had the largest proportion and accounted for more than half of all the patients, followed by chemotherapy (38.3%), targeted therapy (17.8%) and radiotherapy (15.6%). Few patients (9.3%) had received no treatment at the time of the survey.

3.2. Self-Reported Adverse Events

Among the 625 vaccinated patients, the incidence of adverse events was 41.60% (260/625), 38.08% (230/604) and 42.78% (121/283) for the first, second and third doses, respectively. The rate of vaccination adverse events after 48 h decreased significantly compared with the reported rate within 48 h (Figure 1A). Local pain had the highest proportion, followed by fatigue and muscle pain for the first, second and third doses. Other reported adverse events included localized swelling, fever and dizziness. The incidence of diarrhea, nausea and vomiting had the lowest proportion, at less than 1% (Figure 1B).

The association of individual and disease-related factors with adverse events after vaccination was analyzed using univariate and multivariate logistic regression. Table 2 shows that age, time since diagnosis, education, annual income, comorbidities and treatment modalities were all associated with adverse events in the multivariate analysis (Table 2). Old age was associated with decreased incidence of adverse events compared with <40 years of age: aOR, 0.292; 95% CI, 0.125–0.684; p = 0.005; >60 years of age: aOR, 0.107; 95% CI, 0.038–0.303, p < 0.001). Similarly, a time since diagnosis >4 years seemed to be a decreased risk factor for adverse events (time since diagnosis of 4–5 years: aOR,0.453, 95% CI, 0.218–0.941; p = 0.034; >5 years: aOR, 0.348; 95% CI, 0.177–0.682; p = 0.002). Comorbidity (one comorbidity: aOR, 3.851; 95% CI, 2.154–6.882; p < 0.001; two or more comorbidities: OR, 3.099; 95% CI, 1.391–6.902; p = 0.006), receiving endocrine therapy (aOR, 2.157; 95% CI, 1.125–4.136; p = 0.021) and targeted therapy (aOR, 2.474; 95% CI, 1.134–5.397; p = 0.023) were all associated with an increased risk of adverse events. High educational attainment seemed to be associated with an increased incidence of self-reported adverse events (bachelor’s degree and above: aOR, 2.669; 95% CI, 1.200–5.938; p = 0.016).
Figure 1. Self-reported Adverse Events among Vaccinated Patients. (A) Incidence of adverse events within and after 48 h for each dose. (B) Incidence of specific adverse events within 48 h for each dose in reported cases.

3.3. Willingness to Receive Future Vaccination

Willingness to receive a future vaccination/booster shot was studied among the 849 patients who had not complete all three doses of vaccination. Among them, 298 (35.10%) patients were willing to receive an injection in the future. The nonvaccinated patients showed higher acceptance than the vaccinated group (40.24% vs. 27.49%, \( p < 0.001 \)) (Figure 2).

Univariate and multivariate logistic regression analyses were performed to analyze the factors influencing patients’ willingness to receive future vaccination (Table 3). Only time since diagnosis was found to be associated with hesitancy after multivariate analysis. The risk of vaccine hesitancy decreased with the increasing time since diagnosis compared with that within 1 year (time since diagnosis of 1–3 years: \( \text{aOR}, 0.192; 95\% \text{ CI}, 0.115–0.321; p < 0.001 \); 4–5 years: \( \text{aOR}, 0.479; 95\% \text{ CI}, 0.260–0.884; p = 0.019 \); >5 years: \( \text{aOR}, 0.408; 95\% \text{ CI}, 0.215–0.775; p = 0.006 \)).
### Table 2. Univariable and Multivariable logistic regression for adverse events.

| Characteristics                          | Univariable | Multivariable |
|-----------------------------------------|-------------|---------------|
|                                         | OR (95% CI) | p             | OR (95% CI) | p             |
| Age, years                              |             |               |             |               |
| <40                                     | 1           | <0.001        | 0.292       | 0.005         |
| 40–59                                   | 0.264 (0.119–0.586) | <0.001 | 0.107 (0.038–0.303) | <0.001 |
| ≥60                                     | 0.143 (0.056–0.364) | <0.001 |               |               |
| Time since diagnosis, year              |             |               |             |               |
| <1                                      | 1           | 0.653         | 1.096       | 0.820         |
| 1–3                                     | 1.167 (0.595–2.290) | 0.653 | 0.453 (0.218–0.941) | 0.034 |
| 4–5                                     | 0.531 (0.302–0.933) | 0.028 | 0.348 (0.177–0.682) | 0.002 |
| >5                                      | 0.429 (0.262–0.704) | 0.001 |               |               |
| Education                               |             |               |             |               |
| Middle school and below                 | 1           | 0.688         | 1.290       | 0.440         |
| High school                             | 1.123 (0.637–1.978) | 0.688 | 1.529 (0.651–3.589) | 0.330 |
| Technical secondary school              | 1.159 (0.535–2.511) | 0.709 | 1.698 (0.886–3.256) | 0.111 |
| College                                 | 1.419 (0.841–2.394) | 0.190 |               |               |
| Bachelor and above                      | 2.627 (1.404–4.915) | 0.003 | 2.669 (1.200–5.938) | 0.016 |
| Annual income, yuan                     |             |               |             |               |
| <20,000                                 | 1           | 0.691         | 0.938       | 0.824         |
| 20,000–100,000                          | 1.103 (0.680–1.790) | 0.691 | 0.691 (0.331–1.442) | 0.325 |
| 110,000–200,000                         | 1.083 (0.680–1.790) | 0.787 |               |               |
| >200,000                                | 2.023 (0.911–4.492) | 0.083 | 0.980 (0.359–2.677) | 0.969 |
| Number of comorbidities                 |             |               |             |               |
| 0                                       | 1           | 0.001         | 3.851       | <0.001        |
| 1                                       | 2.472 (1.469–4.159) | 0.001 | 1.713 (0.838–3.498) | 0.140 |
| ≥2                                      | 1.713 (0.838–3.498) | 0.140 | 3.099 (1.391–6.902) | 0.006 |
| Number of treatments                     |             |               |             |               |
| 0                                       | 1           | 0.571         | 0.613       | 0.250         |
| 1                                       | 2.462 (1.295–4.682) | 0.006 | 0.583 (0.178–1.915) | 0.374 |
| ≥2                                      | 1.971 (1.323–2.936) | 0.001 | 1.692 (0.824–3.473) | 0.152 |
| Surgery                                 |             |               |             |               |
| Endocrine therapy                       | 1.245 (0.837–1.851) | 0.279 | 2.157 (1.125–4.136) | 0.021 |
| Chemotherapy                            | 1.368 (0.922–2.029) | 0.120 | 1.048 (0.547–2.009) | 0.888 |
| Radiotherapy                            | 0.478 (0.247–0.926) | 0.029 | 1.504 (0.703–3.216) | 0.292 |
| Targeted therapy                        | 2.559 (1.327–4.934) | 0.005 | 2.474 (1.134–5.397) | 0.023 |

OR, odds ratio; CI, confidence interval.

**Figure 2.** Willingness regarding future doses/boosters in all <3 doses group, non-vaccinated group and vaccinated group.
Table 3. Univariable and Multivariable logistic regression for vaccine hesitancy.

| Table 3. Univariable and Multivariable logistic regression for vaccine hesitancy. | Univariable OR (95% CI) | p | Multivariable OR (95% CI) | p |
|---|---|---|---|---|
| Vaccination status | | | | |
| Vaccinated | 1 | | 1 | |
| Non-vaccinated | 0.563 (0.419–0.757) | <0.001 | 1.306 (0.883–1.932) | 0.181 |
| Age, year | | | | |
| <40 | 1 | | 1.117 (0.735–1.698) | 0.604 |
| 40–59 | 0.920 (0.625–1.354) | 0.672 | 0.987 (0.535–1.822) | 0.966 |
| ≥60 | 0.848 (0.487–1.477) | 0.561 | 0.408 (0.215–0.775) | 0.006 |
| Time since diagnosis, year | | | | |
| <1 | 1 | | 1.192 (0.115–0.321) | 0.000 |
| 1–3 | 0.239 (0.164–0.349) | <0.001 | 0.479 (0.260–0.884) | 0.019 |
| 4–5 | 0.573 (0.340–0.967) | 0.037 | 0.408 (0.215–0.775) | 0.006 |
| >5 | 0.495 (0.279–0.879) | 0.016 | 0.408 (0.215–0.775) | 0.006 |
| Marital status | | | | |
| Married | 1 | | 1.306 (0.883–1.932) | 0.181 |
| Unmarried | 1.686 (0.661–4.296) | 0.274 | 1.498 (0.813–2.761) | 0.195 |
| Others | 1.498 (0.813–2.761) | 0.195 | |
| Education | | | | |
| Middle school and below | 1 | | 1 | |
| High school | 0.920 (0.600–1.412) | 0.704 | 1 | |
| Technical secondary school | 1.097 (0.609–1.940) | 0.777 | 1.023 (0.687–1.521) | 0.522 |
| College | 1.137 (0.768–1.683) | 0.522 | 1.137 (0.768–1.683) | 0.522 |
| Bachelor and above | 1.023 (0.687–1.522) | 0.912 | 1.023 (0.687–1.522) | 0.912 |
| Members in family | | | | |
| 1–2 | 1 | | 1.306 (0.883–1.932) | 0.181 |
| 3 | 0.765 (0.488–1.199) | 0.242 | 0.765 (0.488–1.199) | 0.242 |
| 4 | 0.799 (0.482–1.326) | 0.386 | 0.799 (0.482–1.326) | 0.386 |
| ≥5 | 0.763 (0.465–1.252) | 0.284 | 0.763 (0.465–1.252) | 0.284 |
| Annual income, yuan | | | | |
| <20,000 | 1 | | 1.306 (0.883–1.932) | 0.181 |
| 20,000–100,000 | 0.883 (0.615–1.268) | 0.501 | 1.306 (0.883–1.932) | 0.181 |
| 110,000–200,000 | 1.047 (0.685–1.599) | 0.833 | 1.047 (0.685–1.599) | 0.833 |
| >200,000 | 1.231 (0.718–2.111) | 0.450 | 1.231 (0.718–2.111) | 0.450 |
| Number of comorbidities | | | | |
| 0 | 1 | | 1.306 (0.883–1.932) | 0.181 |
| 1 | 0.804 (0.589–1.098) | 0.171 | 0.804 (0.589–1.098) | 0.171 |
| ≥2 | 0.835 (0.548–1.273) | 0.402 | 0.835 (0.548–1.273) | 0.402 |
| Number of treatments | | | | |
| 0 | 1 | | 1.306 (0.883–1.932) | 0.181 |
| 1 | 0.593 (0.240–1.034) | 0.065 | 0.593 (0.240–1.034) | 0.065 |
| ≥2 | 0.700 (0.404–1.212) | 0.203 | 0.700 (0.404–1.212) | 0.203 |
| Treatment | | | | |
| Surgery | 1.214 (0.915–1.611) | 0.178 | 1.214 (0.915–1.611) | 0.178 |
| Endocrine therapy | 0.639 (0.476–0.859) | 0.003 | 0.639 (0.476–0.859) | 0.003 |
| Chemotherapy | 1.459 (1.077–1.977) | 0.015 | 1.459 (1.077–1.977) | 0.015 |
| Radiotherapy | 0.932 (0.646–1.344) | 0.707 | 0.932 (0.646–1.344) | 0.707 |
| Targeted therapy | 0.958 (0.675–1.361) | 0.811 | 0.958 (0.675–1.361) | 0.811 |

OR, odds ratio; CI, confidence interval.

An HBM-based 5-point Likert scale was used to investigate the perceptions among these patients. The distribution and the mean score for each question are shown in Figure 3. A score > 3 means that the patient agrees with the view, and a score < 3 means that the patient disagrees with the view. In this study, question 4 “COVID-19 will cause serious damage to my health,” question 5 “The complications of COVID-19 are very serious” and question 7 “Patients with breast cancer infected with COVID-19 are more severely affected than the rest of the population” had a mean score > 3 (neutral). Question 2 “I think there is a possibility of being infected with COVID-19 currently,” question 3 “I
worry about the likelihood of being infected with COVID-19,” question 17 “I’m willing to receive the COVID-19 vaccine if the media recommends it” and question 18 “I’m willing to receive the COVID-19 vaccine if my family, friends and peers recommend it” had a mean score < 3 (neutral).

Figure 3. Patients perceived vaccine hesitancy towards the COVID-19 vaccine (Based on Healthy Belief Model).

Figure 4 shows the multivariate analysis result of patients’ perceptions and hesitancy (Figure 4). The following four questions were significantly associated with decreased hesitancy: Q1 “I believe that patients with breast cancer are more likely to be infected with COVID-19 than healthy people currently” (perceived susceptibility) (aOR, 0.533; 95% CI, 0.355–0.799, p = 0.002); Q8 “Vaccination makes me less worried about COVID-19 infection” (perceived benefits) (aOR, 0.566; 95% CI, 0.354–0.904, p = 0.017); Q9 “Vaccination reduces my chance of being infected COVID-19 infection” (perceived benefits) (OR, 0.456; 95% CI, 0.264–0.786, p = 0.005); Q16 “I’m willing to receive the COVID-19 vaccine if my doctor recommends it” (action cues) (aOR, 0.325; 95% CI, 0.205–0.514, p < 0.001). Fear of the vaccine’s impact on their cancer condition (Q14, perceived barriers; aOR, 3.346; 95% CI, 1.911–5.859, p < 0.001) was a significant risk factor for hesitancy and refusal of future vaccination.
4. Discussion

The COVID-19 vaccine has played an important role in the prevention and control of the epidemic in the past 2 years. Especially for patients with cancer, vaccination has reduced their adverse outcomes (morbidity, mortality, sequelae, ICU admission and COVID-19 severity) [27,28]. However, vaccine hesitancy remains high in oncology patients, leading to low vaccination rates and an increased medical burden. This study investigated the vaccination status of patients with breast cancer and their cognitive and behavioral patterns regarding vaccine hesitancy.

China was one of the first countries to report COVID-19 cases and successfully develop vaccines. About 3.4 billion vaccine doses have been administered up to 30 June 2022, suggesting a more than 90% vaccination rate among all populations. In our study, only 55.2% of patients were vaccinated. This rate was lower than the current vaccination rate in the general population. Nearly half of the vaccinated patients were within their 1st year of diagnosis, possibly because they were diagnosed with breast cancer only after being vaccinated.

The adverse event rate for each dose was 40% in our study population. Tsai et al. [8] reported a 69.0% rate of local reactions and a 40.0% rate of systemic reactions among individuals with cancer and autoimmune diseases [18]. In a prospective study in Germany, the incidence of post-vaccination adverse events was 63.3% (first dose) and 71.2% (second dose) [29]. The higher incidence of these adverse reactions compared with that in our study may be related to the use of different brands of vaccine. For example, the Pfizer-BioNTech vaccine is the most commonly used brand worldwide but is underutilized in China.

Our results showed that the most common adverse effects after injection were local pain, fatigue and weakness and muscle pain. The incidence of these events was significantly lower 48 h after vaccination, and this result is in agreement with other studies. A patient age > 40 years was associated with reduced adverse events compared with younger age groups. This finding is consistent with that of another study, which indicated that adverse
reactions were more common in younger age groups than in older age groups [30]. This difference may be explained by the reduced immune responses in the older patients due to immunosenescence [31]. In addition, a short time since cancer diagnosis and the presence of two or more comorbidities, as well as receipt of endocrine therapy or targeted therapy, were all associated with an increased incidence of adverse events. However, no serious adverse reactions were reported by the patients.

A vaccine hesitancy rate of approximately 61.9% was reported among the patients who had not yet completed the vaccination/booster; this value is higher than that in other studies (18–74%) [16–20]. Our study showed that a shorter time since diagnosis is a risk factor for vaccine hesitancy. Previous reports have included additional risk factors [17,32], such as a prior history of COVID-19 infection (OR 0.86), a younger age (OR 0.83), conservative political leanings (OR 0.93) and a low education level (OR 0.90).

Logistic regression analysis suggested that perceived susceptibility (Q1, $p = 0.002$), perceived benefit (Q8, $p = 0.017$; Q9, $p = 0.005$), perceived barriers (Q14, $p < 0.001$) and cues to action (Q16, $p < 0.001$) were significantly associated with vaccine hesitancy. Consistent with our findings, Lai et al. [33] reported that the perceived benefits and barriers are important dimensions associated with willingness to receive COVID-19 booster shots. Regarding perceived susceptibility, participants’ perceptions of the risk of SARS-CoV-2 infection tended to be neutral or disagreeable, possibly due to the effective control of the pandemic in China. This intriguing finding may be related to the fallback to normalcy of people’s negative emotions as the epidemic progresses [34]. However, our study found that the individuals’ perceptions of their own risk of infection as patients with cancer were associated with decreased hesitancy. In terms of perceived barriers, patients’ fearful perceptions of possible adverse effects on their cancer were associated with increased hesitancy, and this finding is consistent with results from Turkey [35]. Compared with the media, family, friends and peers, doctor’s advice was significantly associated with decreased vaccine hesitancy. Consistent with other studies, this result suggests that authoritative advice from doctors is an important contributor to patients’ willingness to be vaccinated [17]. Patients have different considerations about their diseases than those of the general population when it comes to vaccination. The core cognitive patterns of patients’ attitudes towards vaccination included the following: belief that they were at higher risk of infection compared to healthy people; a lack of perceived benefit from the vaccination; and fear of any possible negative impacts of the vaccine on their health during their disease. These findings indicate that the information regarding COVID-19 vaccine that is disseminated about among breast cancer patients should be different from that which is targeted at other populations, and that perceived susceptibility, benefits and barriers should be emphasized. In addition, advice from authoritative doctors is a vital cue to action.

**Strengths and Limitations**

This work is the first cross-sectional study of COVID-19 vaccination among patients with breast cancer to capture and analyze such a large volume of data. This research also furthers efforts to increase the vaccination rate among high-risk populations according to the recommendations of the European Society of Medical Oncology [36], the American Society of Clinical Oncology [37] and the National Comprehensive Cancer Network [38]. In addition, details of self-reported adverse events were disclosed and analyzed. Finally, the HBM scale was used to investigate patients’ intentions regarding future vaccinations, providing evidence and recommendations for the current vaccine rollout and behavioral intervention guidance.

This study has some limitations. First, due to the single-centered online nature of the survey, selection bias may affect the generalizability of the results, especially given the participation of relatively few respondents with low educational attainment and fewer older adults (>70 years). Second, this cross-sectional study may not reflect future trends. Third, the multivariables of willingness and attitudes, comprising the 18 items of the scale,
were compressed into binary variables (willingness vs. hesitation/refusal, agreement vs. neutrality/disagreement), possibly causing some information loss.

5. Conclusions

In conclusion, our results show that 55.2% of patients with breast cancer received a COVID-19 vaccine. The incidence of adverse events per dose was around 40%. The rate of vaccine hesitancy was 61.9% among the patients who had not received full vaccination or boosters. For patients with breast cancer, their perceived susceptibility and perceived barriers should be prioritized, and advice from authoritative doctors is a vital cue to action.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/vaccines10091530/s1, Table S1: Scale of vaccine hesitancy; Table S2: Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process (update on 7 July 2022).

Author Contributions: J.C., W.L. and Y.W. contributed to the conception and design of the study. W.L., R.Y., R.C., Y.H., X.Z. and M.X. performed the data curation, investigation, methodology and statistical analysis. W.L. and Y.W. wrote the first draft of the manuscript. Q.W. and Q.L. were responsible for the supervision of the entire study. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the Clinical Research Program for West China Hospital, Sichuan University (2022HXBH021), National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University (Z20192011), The Science and Technology Department of Sichuan Province (2021YJ0012) and the National Natural Science Foundation of China (32071284, 31971141).

Institutional Review Board Statement: This study was approved by the Clinical Test and Biomedical Ethics Committee of West China Hospital, Sichuan University (approval number: 2022649).

Data Availability Statement: The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

Conflicts of Interest: The authors declare that they have no conflict of interest to disclose and have no financial relationships with any biomedical companies.

References

1. Dai, M.; Liu, D.; Liu, M.; Zhou, F.; Li, G.; Chen, Z.; Zhang, Z.; You, H.; Wu, M.; Zheng, Q.; et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020, 10, 783–791. [CrossRef] [PubMed]
2. Liang, W.; Guan, W.; Chen, R.; Wang, W.; Li, J.; Xu, K.; Li, C.; Ai, Q.; Lu, W.; Liang, H.; et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol. 2020, 21, 335–337. [CrossRef]
3. Desai, A.; Gupta, R.; Advani, S.; Ouellette, L.; Kuderer, N.M.; Lyman, G.H.; Li, A. Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta-analysis of cohort studies. Cancer 2021, 127, 1459–1468. [CrossRef] [PubMed]
4. Sidaway, P. COVID-19 and cancer: What we know so far. Nat. Rev. Clin. Oncol. 2020, 17, 336. [CrossRef]
5. Giannakoulis, V.G.; Papoutsi, E.; Siempos, I.I. Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data. JCO Glob. Oncol. 2020, 6, 799–808. [CrossRef] [PubMed]
6. Tagliamento, M.; Agostinetto, E.; Bruzzone, M.; Ceppi, M.; Saini, K.S.; de Azambuja, E.; Punie, K.; Westphalen, C.B.; Morgan, G.; Pronzato, P.; et al. Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 2021, 163, 103365. [CrossRef]
7. Ozdemir, N.; Dizdar, O.; Yazici, O.; Aksoy, S.; Dede, D.S.; Budakoglu, B.; Metan, G.; Alp, A.; Budakoglu, I.I.; Oksuozoglu, O.B.C.; et al. Clinical features and outcomes of COVID-19 in patients with solid tumors: Turkish National Registry Data. Int. J. Cancer 2020, 148, 2407–2415. [CrossRef]
8. Yang, K.; Sheng, Y.; Huang, C.; Jin, Y.; Xiong, N.; Jiang, K.; Lu, H.; Liu, J.; Yang, J.; Dong, Y.; et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: A multicentre, retrospective, cohort study. Lancet Oncol. 2020, 21, 904–913. [CrossRef]
9. Ribas, A.; Sengupta, R.; Locke, T.; Zaidi, S.K.; Campbell, K.M.; Carethers, J.M.; Jaffee, E.M.; Wherry, E.J.; Soria, J.C.; D'Souza, G.; et al. Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. *Cancer Discov.* 2021, 11, 233–236. [CrossRef] [PubMed]

10. Feniot, C.; Teixeira, L.; Fourati, S.; Melica, G.; Lelievre, J.D.; Gallien, S.; Zalcman, G.; Pawlotsky, J.M.; Tournigand, C. SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents. *JAMA Oncol.* 2022, 8, 612–617. [CrossRef]

11. Lee, L.Y.W.; Starkey, T.; Ionescu, M.C.; Little, M.; Tilby, M.; Tripathy, A.R.; McKenzie, H.S.; Al-Hajji, Y.; Barnard, M.; Benny, L.; et al. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCECP): A population-based test-negative case-control study. *Lancet Oncol.* 2022, 23, 748–757. [CrossRef]

12. Brodziak, A.; Sigorski, D.; Osmola, M.; Wilk, M.; Gawlik-Urban, A.; Kiszka, J.; Machulska-Ciuraj, K.; Sobczuk, P. Attitudes of Patients with Cancer towards Vaccinations-Results of Online Survey with Special Focus on the Vaccination against COVID-19. *Vaccines 2021*, 9, 411. [CrossRef]

13. Kosaka, M.; Koteru, Y.; Tsuda, K.; Takahashi, K.; Hamaki, T.; Kusumi, E.; Kami, M.; Tanimoto, T. Influenza vaccination uptake and attitudes among adult cancer patients: A web-based questionnaire survey before the 2020/2021 season. *Hum. Vaccines Immunother.* 2021, 17, 5509–5513. [CrossRef]

14. Vinograd, I.; Baslo, R.; Elakim-Raz, N.; Farbman, L.; Taha, A.; Sakhnini, A.; Lador, A.; Stemmer, S.M.; Gafter-Gvili, A.; Fraser, D.; et al. Factors associated with influenza vaccination among adult cancer patients: A case-control study. *Clin. Microbiol. Infect.* 2014, 20, 899–905. [CrossRef] [PubMed]

15. MacDonald, N.E.; Hestiany, S.W.G.O.V. Vaccine hesitancy: Definition, scope and determinants. *Vaccine* 2015, 33, 4161–4164. [CrossRef]

16. Overheu, O.; Lendowski, S.; Quast, D.R.; Marheinecke, C.S.; Kourti, E.; Lugnier, C.; Andreica, I.; Kiltz, U.; Pfaender, S.; Reinacher-Schick, A. Attitude towards and perception of individual safety after SARS-CoV-2 vaccination among German cancer patients. *J. Cancer Res. Clin. Oncol.* 2022, 1–8. [CrossRef] [PubMed]

17. Chun, J.Y.; Kim, S.I.; Park, E.Y.; Park, S.Y.; Koh, S.J.; Cha, Y.; Yoo, H.J.; Joung, J.Y.; Yoon, H.M.; Eom, B.W.; et al. Cancer Patients’ Willingness to Take COVID-19 Vaccine: A Nationwide Multicenter Survey in Korea. *Cancers 2021*, 13, 3883. [CrossRef] [PubMed]

18. Hong, J.; Xu, X.W.; Yang, J.; Zheng, J.; Dai, S.M.; Zhou, J.; Zhang, Q.M.; Ruan, Y.; Ling, C.Q. Knowledge about, attitude and acceptance towards, and predictors of intention to receive the COVID-19 vaccine among cancer patients in Eastern China: A cross-sectional survey. *J. Integr. Med.* 2021, 20, 34–44. [CrossRef]

19. Villarreal-Garza, C.; Vaca-Cartagena, B.F.; Becerril-Gaitan, A.; Ferrigno, A.S.; Mesa-Chavez, F.; Platas, A.; Platas, A. Attitudes and Factors Associated With COVID-19 Vaccine Hesitancy among Patients with Breast Cancer. *JAMA Oncol.* 2021, 7, 1242–1244. [CrossRef] [PubMed]

20. Peng, X.; Gao, P.; Wang, Q.; Wu, H.G.; Yan, Y.L.; Xia, Y.; Wang, J.Y.; Lu, F.; Pan, H.; Yang, Y.; et al. Prevalence and Impact Factors of COVID-19 Vaccination Hesitancy among Breast Cancer Survivors: A Multicenter Cross-Sectional Study in China. *Front. Med.* 2021, 8, 741204. [CrossRef] [PubMed]

21. Jones, C.L.; Jensen, J.D.; Scherr, C.L.; Brown, N.R.; Christy, K.; Weaver, J. The Health Belief Model as an explanatory framework in communication research: Exploring parallel, serial, and mediated moderation. *Health Commun.* 2015, 30, 556–576. [CrossRef]

22. Lai, J.T.; Kim, J.H.; Yang, X.; Tsui, H.Y. Cross-sectional and longitudinal factors predicting influenza vaccination in Hong Kong Chinese elderly aged 65 and above. *J. Infect.* 2008, 56, 460–468. [CrossRef]

23. Santos, A.J.; Kislaya, I.; Machado, A.; Nunes, B. Beliefs and attitudes towards the influence vaccine in high-risk individuals. *Epidemiol. Infect.* 2017, 145, 1786–1796. [CrossRef] [PubMed]

24. Donadiki, E.M.; Jimenez-Garcia, R.; Hernandez-Barrera, V.; Sourtzi, P.; Carrasco-Garrido, P.; de Andres, A.L.; Jimenez-Trujillo, I.; Velonakis, E.G. Health Belief Model applied to non-compliance with HPV vaccine among female university students. *Public Health* 2014, 128, 268–273. [CrossRef]

25. Wagner, A.L.; Boulton, M.L.; Sun, X.; Mukherjee, B.; Huang, Z.; Harmsen, I.A.; Ren, J.; Zikmund-Fisher, B.J. Perceptions of measles, pneumonia, and meningitis vaccines among caregivers in Shanghai, China, and the health belief model: A cross-sectional study. *BMC Pediatr.* 2017, 17, 143. [CrossRef]

26. Walker, A.N.; Zhang, T.; Peng, X.Q.; Ge, J.J.; Gu, H.; You, H. Vaccine Acceptance and Its Influencing Factors: An Online Cross-Sectional Study Among International College Students Studying in China. *Vaccines 2021*, 9, 585. [CrossRef]

27. Di Felice, G.; Visci, G.; Teglia, F.; Angelini, M.; Boffetta, P. Effect of cancer on outcome of COVID-19 patients: A systematic review and meta-analysis of studies of unvaccinated patients. *eLife* 2022, 11, e74634. [CrossRef]

28. Pinato, D.J.; Ferrante, D.; Aguilar-Company, J.; Bower, M.; Salazar, R.; Mirallas, O.; Sureda, A.; Bertuzzi, A.; Brunet, J.; Lambertini, M.; et al. Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. *Eur. J. Cancer 2022*, 171, 64–74. [CrossRef]

29. Forster, M.; Wuerstlein, R.; Koenig, A.; Amann, N.; Beyer, S.; Kaltofen, T.; Degenhardt, T.; Burges, A.; Trillas, F.; Mahner, S.; et al. COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective. *Breast 2021*, 60, 214–222. [CrossRef]
30. Shulman, R.M.; Weinberg, D.S.; Ross, E.A.; Ruth, K.; Rall, G.F.; Olszanski, A.J.; Helstrom, J.; Hall, M.J.; Judd, J.; Chen, D.Y.T.; et al. Adverse Events Reported by Patients with Cancer after Administration of a 2-Dose mRNA COVID-19 Vaccine. *J. Natl. Compr. Cancer Netw.* **2022**, *20*, 160–166. [CrossRef]

31. Ciabattini, A.; Nardini, C.; Santoro, F.; Garagnani, P.; Franceschi, C.; Medaglini, D. Vaccination in the elderly: The challenge of immune changes with aging. *Semin. Immunol.* **2018**, *40*, 83–94. [CrossRef]

32. Tsai, R.; Hervey, J.; Hoffman, K.; Wood, J.; Johnson, J.; Deighton, D.; Clermont, D.; Loew, B.; Goldberg, S.L. COVID-19 Vaccine Hesitancy and Acceptance Among Individuals with Cancer, Autoimmune Diseases, or Other Serious Comorbid Conditions: Cross-sectional, Internet-Based Survey. *JMIR Public Health Surveill.* **2022**, *8*, e29872. [CrossRef] [PubMed]

33. Lai, X.; Zhu, H.; Wang, J.; Huang, Y.; Jing, R.; Lyu, Y.; Zhang, H.; Feng, H.; Guo, J.; Fang, H. Public Perceptions and Acceptance of COVID-19 Booster Vaccination in China: A Cross-Sectional Study. *Vaccines* **2021**, *9*, 1461. [CrossRef] [PubMed]

34. Li, Y.; Luan, S.; Li, Y.; Hertwig, R. Changing emotions in the COVID-19 pandemic: A four-wave longitudinal study in the United States and China. *Soc. Sci. Med.* **2021**, *285*, 114222. [CrossRef] [PubMed]

35. Mejri, N.; Berrazega, Y.; Ouertani, E.; Rachdi, H.; Bohli, M.; Kochbati, L.; Boussen, H. Understanding COVID-19 vaccine hesitancy and resistance: Another challenge in cancer patients. *Supportive Care Cancer* **2022**, *30*, 289–293. [CrossRef] [PubMed]

36. European Society of Medical Oncology. ESMO Statements for Vaccination against COVID-19 in Patients with Cancer. Available online: https://www.esmo.org/covid-19-and-cancer/covid-19-vaccination (accessed on 18 May 2021).

37. American Society of Clinical Oncology. COVID-19 Vaccines & Patients with Cancer. Available online: https://www.asco.org/asco-coronavirus-resources/covid-19-vaccines-patients-cancer (accessed on 18 May 2021).

38. National Comprehensive Cancer Network. Recommendations of the NCCN COVID-19 Vaccination Advisory Committee. Available online: https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v2-0.pdf (accessed on 18 May 2021).